Evidence map›Paper›PMID 25242656›Full record

ArticleBMC medicine2014

Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.

Ali A Mokdad, Alan D Lopez, Saied Shahraz, Rafael Lozano, Ali H Mokdad, Jeff Stanaway, Christopher J L Murray, Mohsen Naghavi

2 registry-linked trialsAbstract read
In one paragraph

Article in BMC medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 493 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
493citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03342560 nacompletednot on this mapstarted 2017, after this paper: background citation

Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography

TypeinterventionalSponsorMassachusetts General HospitalRan2017 to 2018Enrolled30ConditionsLiver Fibrosis, Liver DiseasesArmsSonographic SWE measurements with 4 different ultrasound systems
NCT04421118 unknown statusnot on this mapstarted 2021, after this paper: background citation

Study on The Precise Selection of Stent Diameter for Portal Hypertension Patients With Transjugular Intrahepatic Portosystemic Shunt Based on Computational Fluid Dynamics

TypeobservationalSponsorFirst Affiliated Hospital of Zhejiang UniversityRan2021 to 2024Enrolled60ConditionsCompensated Advanced Chronic Liver Disease, Portal HypertensionArmsa non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient
3 · Its place in the literature

Who cites it

493 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Training hepatologists in alcohol use disorder management: a pilot study.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Identification of Hepatic Fibrosis and Steatosis via A Point-of-Care Transient Elastography System With Integrated AI.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  18. Review
  19. Observational
  20. Article

433 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ali A Mokdad
Alan D Lopez
Saied Shahraz
Rafael Lozano
Ali H Mokdad
Jeff Stanaway
Christopher J L Murray
Mohsen Naghavi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver cirrhosis is a major yet largely preventable and underappreciated cause of global health loss. Variations in cirrhosis mortality at the country level reflect differences in prevalence of risk factors such as alcohol use and hepatitis B and C infection. We estimated annual age-specific mortality from liver cirrhosis in 187 countries between 1980 and 2010.

methodsWe systematically collected vital registration and verbal autopsy data on liver cirrhosis mortality for the period 1980 to 2010. We corrected for misclassification of deaths, which included deaths attributed to improbable or nonfatal causes. We used ensemble models to estimate liver cirrhosis mortality with uncertainty by age, sex, country and year. We used out-of-sample predictive validity to select the optimal model.

resultsGlobal liver cirrhosis deaths increased from around 676,000 (95% uncertainty interval: 452,863 to 1,004,530) in 1980 to over 1 million (1,029,042; 670,216 to 1,554,530) in 2010 (about 2% of the global total). Over the same period, the age-standardized cirrhosis mortality rate decreased by 22%. This was largely driven by decreasing cirrhosis mortality rates in China, the US and countries in Western Europe. In 2010, Egypt, followed by Moldova, had the highest age-standardized cirrhosis mortality rates, 72.7 and 71.2 deaths per 100,000, respectively, while Iceland had the lowest. In Egypt, almost one-fifth (18.1%) of all deaths in males 45- to 54-years old were due to liver cirrhosis. Liver cirrhosis mortality in Mexico is the highest in Latin America. In France and Italy, liver cirrhosis mortality fell by 50% to 60%; conversely, in the United Kingdom, mortality increased by about one-third. Mortality from liver cirrhosis was also comparatively high in Central Asia countries, particularly Mongolia, Uzbekistan and Kyrgyzstan, and in parts of sub-Saharan Africa, notably Gabon.

conclusionsLiver cirrhosis is a significant cause of global health burden, with more than one million deaths in 2010. Our study identifies areas with high and/or rapidly increasing mortality where preventive measures to control and reduce liver cirrhosis risk factors should be urgently strengthened.

Indexed as

Aged, 80 and overChinaEuropeFemaleFranceHumansItalyLiver CirrhosisMaleMexicoMiddle AgedPrevalenceRisk FactorsUnited KingdomYoung Adult

Identifiers

PMID25242656
PMCPMC4169640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.